Prospects for the Use of ATR Inhibitors to Treat Cancer

ATR is an apical kinase in one of the DNA-damage induced checkpoint pathways. Despite the development of inhibitors of kinases structurally related to ATR, as well as inhibitors of the ATR substrate Chk1, no ATR inhibitors have yet been developed. Here we review the effects of ATR downregulation in...

Descripción completa

Detalles Bibliográficos
Autores principales: Wagner, Jill M., Kaufmann, Scott H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033983/
https://www.ncbi.nlm.nih.gov/pubmed/27713304
http://dx.doi.org/10.3390/ph3051311
_version_ 1782317909955051520
author Wagner, Jill M.
Kaufmann, Scott H.
author_facet Wagner, Jill M.
Kaufmann, Scott H.
author_sort Wagner, Jill M.
collection PubMed
description ATR is an apical kinase in one of the DNA-damage induced checkpoint pathways. Despite the development of inhibitors of kinases structurally related to ATR, as well as inhibitors of the ATR substrate Chk1, no ATR inhibitors have yet been developed. Here we review the effects of ATR downregulation in cancer cells and discuss the potential for development of ATR inhibitors for clinical use.
format Online
Article
Text
id pubmed-4033983
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-40339832014-05-27 Prospects for the Use of ATR Inhibitors to Treat Cancer Wagner, Jill M. Kaufmann, Scott H. Pharmaceuticals (Basel) Review ATR is an apical kinase in one of the DNA-damage induced checkpoint pathways. Despite the development of inhibitors of kinases structurally related to ATR, as well as inhibitors of the ATR substrate Chk1, no ATR inhibitors have yet been developed. Here we review the effects of ATR downregulation in cancer cells and discuss the potential for development of ATR inhibitors for clinical use. MDPI 2010-04-28 /pmc/articles/PMC4033983/ /pubmed/27713304 http://dx.doi.org/10.3390/ph3051311 Text en © 2010 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Wagner, Jill M.
Kaufmann, Scott H.
Prospects for the Use of ATR Inhibitors to Treat Cancer
title Prospects for the Use of ATR Inhibitors to Treat Cancer
title_full Prospects for the Use of ATR Inhibitors to Treat Cancer
title_fullStr Prospects for the Use of ATR Inhibitors to Treat Cancer
title_full_unstemmed Prospects for the Use of ATR Inhibitors to Treat Cancer
title_short Prospects for the Use of ATR Inhibitors to Treat Cancer
title_sort prospects for the use of atr inhibitors to treat cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033983/
https://www.ncbi.nlm.nih.gov/pubmed/27713304
http://dx.doi.org/10.3390/ph3051311
work_keys_str_mv AT wagnerjillm prospectsfortheuseofatrinhibitorstotreatcancer
AT kaufmannscotth prospectsfortheuseofatrinhibitorstotreatcancer

Ejemplares similares